Ads
related to: stelara for crohn's disease- Patient Resources
Information About Injecting
Cost Support and More
- Save on STELARA®
Eligible Patients pay $5 copay/dose
2020 additional requirements apply
- Cost Support Information
Learn About Cost Support Options
View Support Program Info.
- About STELARA®
Information on Getting Started
Learn More About STELARA® Today
- Patient Resources
Search results
From Nurse To Patient: My Journey With Crohn’s Disease
Women's Health via Yahoo News· 2 years agoAs a healthcare professional, Alison spent her days doing endoscopies, which are one of the many...
J&J’s Tremfya superior to Stelara in Phase II/III Chron’s disease trials
Clinical Trials Arena via Yahoo Finance· 1 week agoJohnson and Johnson’s Johnson and Johnson’s Tremfya (guselkumab) was superior to its Stelara...
AbbVie's (ABBV) Skyrizi Crohn's Disease Study Meets Goals
Zacks via Yahoo Finance· 9 months agoAbbVie's (ABBV) Skyrizi met both primary endpoints of non-inferiority for clinical remission at week...
FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq
Benzinga via Yahoo Finance· 1 year agoThe FDA approved AbbVie Inc's (NASDAQ: ABBV) Rinvoq (upadacitinib) for moderately to severely active...
Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study
Zacks via Yahoo Finance· 2 months agoBristol Myers BMY announced that a late-stage study on orally-administered Zeposia (ozanimod) in...
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
Zacks via Yahoo Finance· 1 week agoShares of Eli Lilly LLY rose nearly 3% on Tuesday after it reported detailed one-year results from...
Analysis-Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast
Reuters via Yahoo News· 12 months agoJohnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster...
What Could This Drug News Mean for AbbVie?
Motley Fool· 2 years agoIn late July, AbbVie (NYSE: ABBV) applied for a new indication with the European Medicines Agency (EMA) for Rinvoq to treat adult patients with...
Johnson & Johnson Clocks 12% Q4 Revenue Growth, Led By Cancer and Crohn's Disease Drugs
Benzinga via Yahoo Finance· 4 months agoOn Tuesday, Johnson & Johnson (NYSE:JNJ) reported fourth-quarter 2023 adjusted earnings of $2.29 per...
IBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High
Investor's Business Daily· 1 week agoEli Lilly is Tuesday's IBD Stock Of The Day after shares surged into a buy zone, again, on promising...
Ads
related to: stelara for crohn's disease